Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas

International Journal of Cancer

Volumn 115, Issue 5, 2005, Pages 734-741

  Körner, Meike ^a   Waser, Beatrice ^a   Reubi, Jean Claude ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Nephroblastoma; NPY receptor; Receptor autoradiography; Renal cell carcinoma

Indexed keywords

IODINE 125; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; PEPTIDE YY; RECEPTOR SUBTYPE;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; BINDING COMPETITION; BLOOD VESSEL; CLINICAL ARTICLE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; KIDNEY CARCINOMA; MALE; NEPHROBLASTOMA; NERVE FIBER; PRIORITY JOURNAL; RECEPTOR DENSITY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NERVE FIBERS; RECEPTORS, NEUROPEPTIDE Y; WILMS TUMOR;

EID: 20144374787     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20948     Document Type: Article

References (46)

1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
2. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. Somatostatin receptor scintigraphy. New York: Raven Press, 1995, 1-50.
3. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, Weber HC, Stewart CA, Jensen RT. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann Intern Med 1996;125:26-34.
4. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43:610-6.
5. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, de Jong M, Srinivasan A, Erion JL, Krenning E. Treatment of patients with gastro-enteropancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417-22.
6. Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T. XVI International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y. peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 1998;50:143-50.
7. Norvell JE, MacBride RG. Neuropeptide Y (NPY)-like immunoreactive nerve fibers in the human and monkey (Macaca fascicularis) kidney. Neurosci Lett 1989;23:63-7.
8. Reubi JC, Gugger M, Waser B, Schaer JC. Y1-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 2001;61:4636-41.
9. Körner M, Waser B, Reubi JC. Neuropeptide Y receptor expression in human primary ovarian neoplasms. Lab Invest 2004;84:71-80.
10. Körner M, Waser B, Reubi JC. High expression of NPY receptors in tumors of the human adrenal gland and extraadrenal paraganglia. Clin Cancer Res 2004;10:8426-33.
11. Langer M, La Bella R, Garcia-Garayoa E, Beck-Sickinger AG. 99mTc-labeled neuropeptide Y analogues as potential tumor imaging agents. Bioconjug Chem 2001;12:1028-34.
12. Langer M, Kratz F, Rothen-Rutishauser B, Wunderli-Allenspach H, Beck-Sickinger AG. Novel peptide conjugates for tumor-specific chemotherapy. J Med Chem 2001;44:1341-8.
13. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
14. Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr Treat Options Oncol 2003;4:385-90.
15. Martel CL, Lara PN. Renal cell carcinoma: current status and future directions. Crit Rev Oncol Hematol 2003;45:177-90.
16. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003;27:612-24.
17. D'Angio GJ. Pre- or post-operative treatment for Wilms tumor? Who, what, when, where, how, why-and which. Med Pediatr Oncol 2003;41:545-9.
18. Ludin A, Macklis RM. Radiotherapy for pediatric genitourinary tumors. Its role and long-term consequences. Urol Clin North Am 2000;27:553-62.
19. Shearer P, Kapoor G, Beckwith JB, Takashima J, Breslow N, Green DM. Secondary acute myelogenous leukemia in patients previously treated for childhood renal tumors: a report from the National Wilms Tumor Study Group. J Pediatr Hematol Oncol 2001;23:109-11.
20. Pritchard-Jones K. Controversies and advances in the management of Wilms' tumour. Arch Dis Child 2002;87:241-4.
21. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press.
22. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
23. Reubi JC, Kvols L. Somatostatin receptors in human renal cell carcinomas. Cancer Res 1992;52:6074-8.
24. Aicher SA, Springston M, Berger SB, Reis DJ, Wahlestedt C. Receptor-selective analogs demonstrate NPY/PYY receptor heterogeneity in rat brain. Neurosci Lett 1991;130:32-6.
25. Hacker GW, Bishop AE, Terenghi G, Varndell IM, Aghahowa J, Pollard K, Thurner J, Polak JM. Multiple peptide production and presence of general neuroendocrine markers detected in 12 cases of human phaeochromocytoma and in mammalian adrenal glands. Virchows Arch A Pathol Anat Histopathol 1988;412:399-411.
26. El-Salhy M, Grimelius L, Wilander E, Ryberg B, Terenius L, Lundberg JM, Tatemoto K. Immunocytochemical identification of polypeptide YY (PYY) cells in the human gastrointestinal tract. Histochemistry 1983;77:15-23.
27. Wharton J, Gordon L, Byrne J, Herzog H, Selbie LA, Moore K, Sullivan MH, Elder MG, Moscoso G, Taylor KM, Shine J, Polak JM. Expression of the human neuropeptide tyrosine Y1 receptor. Proc Natl Acad Sci USA 1993;90:687-91.
28. Bischoff A, Michel MC. Renal effects of neuropeptide Y. Pflugers Arch 1998;435:443-53.
29. Rudolf K, Eberlein W, Engel W, Wieland HA, Willim KD, Entzeroth M, Wienen W, Beck-Sickinger A, Doods HN. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur J Pharmacol 1994;271:R11-3.
30. Dumont Y, Cadieux A, Doods H, Hong Pheng L, Abounader R, Hamel E, Jacques D, Regoli D, Quirion R. BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y2 receptor antagonist. Br J Pharmacol 2000;129:1075-88.
31. Cabrele C, Langer M, Bader R, Wieland HA, Doods HN, Zerbe O, Beck-Sickinger AG. The first selective agonist for the neuropeptide Y Y5 receptor increases food intake in rats. J Biol Chem 2000;275:36043-8.
32. D'Andrea V, Malinovsky L, Berni A, Biancari F, Biassoni L, DiMatteo FM, Corbellini L, Falvo L, Santoni F, Spyrou M, Antoni ED. The immunolocalization of PGP 9.5 in normal human kidney and renal cell carcinoma. G Chir 1997;18:521-4.
33. Seifert P, Spitznas M. Tumours may be innervated. Virchows Arch 2001;438:228-31.
34. Seifert P, Benedic M, Effert P. Nerve fibers in tumors of the human urinary bladder. Virchows Arch 2002;440:291-7.
35. Li Q, Johansson H, Grimelius L. Innervation of human adrenal gland and adrenal cortical lesions. Virchows Arch 1999;435:580-9.
36. Shorter NA, Pence JC. Retinoic acid-induced regulation of neuropeptide Y receptor expression and function in the neuroepithelioma line SK-N-MC. J Pediatr Surg 1997;32:721-3.
37. Snow RM, Schellhammer PF. Spontaneous regression of metastatic renal cell carcinoma. Urology 1982;20:177-81.
38. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol 1989;63:128-31.
39. Whang YE, Godley PA. Renal cell carcinoma. Curr Opin Oncol 2003;15:213-6.
40. Grosfeld JL. Risk-based management of solid tumors in children. Am J Surg Pathol 2000;180:322-7.
41. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000;41:1704-13.
42. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999;141:1-14.
43. Plonowski A, Schally AV, Nagy A, Kiaris H, Hebert F, Halmos G. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238. Cancer Res 2000;60:2996-3001.
44. Moch H, Gasser T, Amin AB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000;89:604-14.
45. 111In-DPTA-D-Phe1]-octreotide scintigraphy in the management of patients with advanced renal cell carcinoma. Cancer Biother Radiopharm 1999;14:59-64.
46. Flamen P, Bossuyt A, De Greve J, Pipeleers-Marichal M, Keuppens F, Somers G. Imaging of renal cell cancer with radiolabelled octreotide. Nucl Med Commun 1993;14:873-7.